Glaukos Corporation (GKOS) News

Glaukos Corporation (GKOS)

Today's Latest Price: $67.02 USD

2.73 (4.25%)

Updated Nov 23 4:00pm

Add GKOS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

Filter GKOS News Items

GKOS News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos Is Still A Good Long-Term Value Despite A Tough 2020

Glaukos (GKOS) is a long-term holding of mine that has been heavily impacted by the COVID-19 pandemic. Given that the vast majority of Glaukos’ revenue comes from elective surgery, many of the procedures that would have led to product sales for the company just haven’t been taking place. I last...

Andy Jones on Seeking Alpha | August 20, 2020

Glaukos Corporation (GKOS) Tom Burns on Q2 2020 Results - Earnings Call Transcript

Glaukos Corporation (GKOS) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Chris Lewis - Director of Investor Relations, Corporate Strategy & Development Tom Burns - President & Chief Executive Officer Joe Gilliam - Chief Financial Officer Chris Calcaterra - Chief Operating Officer Conference Call Participants Brian...

SA Transcripts on Seeking Alpha | August 9, 2020

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 6, 2020.

Yahoo | July 20, 2020

Here is What Hedge Funds Think About Glaukos Corporation (GKOS)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | June 28, 2020

Here's Why You Should Retain Glaukos in Your Portfolio Now

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

Yahoo | June 18, 2020

Glaukos prices $250M convertible debt offering

Glaukos (GKOS) has priced its private offering of $250M (from $200M) aggregate principal amount of 2.75% Convertible Senior Notes due 2027.Initial purchasers will have an option to purchase up to an additional $37.5M of notes. The initial conversion rate is 17.8269 common shares per $1,000 principal amount of notes (~$56.10/share)....

Seeking Alpha | June 9, 2020

Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that in light of the company’s offering of its 2.75% Convertible Senior Notes due 2027, which is expected to close on June 11, 2020, subject to customary closing conditions, management will no longer be participating in its previously announced virtual fireside presentation and associated webcast at the William Blair 40th Annual Growth Stock Conference, previously scheduled for Wednesday, June 10, 2020, at 3:20 p.m. CDT. Management will continue to participate in the conference’s other investor forums.

Yahoo | June 9, 2020

Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes

Glaukos Corporation (NYSE: GKOS) (the "Company" or "Glaukos"), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027 (the "notes"). The offering size was increased from the previously announced offering size of $200 million aggregate principal amount of notes. The notes were offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Glaukos has granted to the initial purchasers of the notes a 13-day option to purchase up to a...

Yahoo | June 9, 2020

Glaukos launches $200M convertible debt offering

Glaukos (GKOS) intends to offer $200M aggregate principal amount of Convertible Senior Notes due 2027 in a private offering.Initial purchasers will have an option to purchase up to an additional $30M of the notes. Interest rate, initial conversion rate and other terms of the notes are not yet determined.Net proceeds...

Seeking Alpha | June 8, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5478 seconds.